Bacopa

Bacopa monnieri standardized extract inhibits CYP2C9 (IC50 36.49 µg/mL, Ki 12.5 µg/mL) via non-competitive inhibition, reducing hepatic metabolism of S-warfarin. At estimated gut concentrations after oral dosing (~600 µg/mL), CYP2C9 activity is reduced to <10% of baseline. This may increase warfarin plasma levels and anticoagulant effect.

Monitor INR closely if Bacopa is initiated, dose-adjusted, or discontinued in patients on warfarin. Counsel patients to report unusual bruising or bleeding. Consider alternative herbal nootropics with fewer CYP2C9 interactions if warfarin management is complex.

Bacopa monnieri extract inhibits CYP3A4 (competitive, IC50 83.95 µg/mL) and CYP2C19 (IC50 23.67 µg/mL), both responsible for amitriptyline metabolism. Animal studies show Bacopa pretreatment increased amitriptyline AUC and Cmax, decreased oral clearance, and reduced first-pass metabolism by 2-fold via intestinal CYP3A inhibition. This could increase TCA plasma concentrations and toxicity risk.

Avoid concurrent use where possible. If co-administered, monitor for signs of TCA toxicity (dry mouth, blurred vision, constipation, tachycardia, urinary retention, sedation). TCA dose reduction may be needed. The interaction is likely most pronounced with intestinal CYP3A4-sensitive TCAs.

Bacopa monnieri inhibits CYP1A2 (IC50 52.20 µg/mL), CYP2C9, CYP2C19, and CYP3A4, all involved in SSRI metabolism. Additionally, Bacopa modulates serotonin receptors and may increase serotonergic tone. Case reports document adverse events (myalgia, epigastric pain, nausea, restless legs syndrome, cough) when combined with escitalopram; cholinergic toxicity (hyperhidrosis, malaise, tachycardia) also reported with CYP-metabolised drugs. Retrospective pharmacovigilance identified 7 adverse event cases with Withania/adaptogen + SSRI interactions sharing similar mechanisms.

Avoid combining Bacopa with SSRIs unless under close medical supervision. If used together, monitor for symptoms of serotonin excess (agitation, tachycardia, hyperthermia, tremor) and for SSRI toxicity from reduced clearance. Discontinue Bacopa and seek immediate medical attention if serotonin syndrome signs appear.

Phenytoin is primarily metabolized by CYP2C9 (~90%) and CYP2C19. Bacopa monnieri inhibits both CYP2C9 (IC50 36.49 µg/mL) and CYP2C19 (IC50 23.67 µg/mL) non-competitively. This dual inhibition may reduce phenytoin clearance and elevate plasma concentrations into the toxic range. Phenytoin has a narrow therapeutic index (10–20 mg/L) and small changes in plasma levels can cause toxicity.

Monitor phenytoin plasma levels closely if Bacopa is started or discontinued. Warn patients of early phenytoin toxicity signs: nystagmus, ataxia, diplopia, slurred speech, confusion. Dose reduction of phenytoin may be required. Consider safer alternatives to Bacopa in patients on phenytoin.

Bacopa monnieri inhibits CYP3A4 and CYP2D6, the principal enzymes metabolizing cevimeline and other cholinergic agonists. Additionally, Bacopa itself enhances cholinergic neurotransmission (via acetylcholinesterase inhibition). Combined use may dramatically increase cevimeline plasma concentrations and cholinergic receptor stimulation, resulting in toxicity. A published case report described cholinergic toxicity (hyperhidrosis, malaise, nausea, tachycardia) in a patient taking a Bacopa-containing supplement with cevimeline.

Avoid concurrent use of Bacopa with cevimeline or other cholinergic agonists (pilocarpine, bethanechol). If overlap occurs, monitor closely for cholinergic toxicity: excessive sweating, salivation, lacrimation, bronchospasm, bradycardia, nausea, vomiting, diarrhea. Discontinue Bacopa immediately if toxicity is suspected.

Animal studies show that Bacopa monnieri extract significantly increases serum thyroxine (T4) levels, possibly by stimulating thyroid hormone synthesis or reducing hepatic clearance. This could augment the effects of levothyroxine (risk of hyperthyroidism) or reduce the efficacy of anti-thyroid drugs (methimazole, carbimazole) used in hyperthyroidism management.

Patients on thyroid hormone replacement should have TSH and free T4 monitored if starting Bacopa, and be alert for symptoms of hyperthyroidism (palpitations, weight loss, tremor, heat intolerance). Patients with hyperthyroidism on anti-thyroid agents should avoid Bacopa. Consult an endocrinologist before combining.